JAMA network open

Kidney Function After COVID-19 in Children and Teens

Updated

Abstract

Among 1,900,146 pediatric patients, SARS-CoV-2 infection was associated with a higher risk of new-onset chronic kidney disease (CKD) stage 2 or higher.

  • SARS-CoV-2 infection is linked to an increased risk of CKD stage 2 or higher (HR, 1.17).
  • The risk of CKD stage 3 or higher is also elevated in children with COVID-19 (HR, 1.35).
  • Children with preexisting CKD showed a higher risk of composite kidney events following SARS-CoV-2 infection (HR, 1.15).
  • Acute-phase AKI in pediatric patients is associated with increased risks for adverse kidney outcomes (HR, 1.29) at 90 to 179 days.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict of Interest Disclosures: Dr Arnold reported receiving grant support from Pfizer Inc and Amgen Inc outside the submitted work. Dr Blecker reported ownership of Vineland Dialysis outside the submitted work. Dr Reynolds Geary reported receiving grant support from the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. Dr Jhaveri reported receiving personal fees from AstraZeneca, CSL Seqirus, Sanofi SA, and Gilead Sciences Inc, grant support from GSK, and an editorial stipend from the Pediatric Infectious Diseases Society outside the submitted work and having a patent for UpToDate with royalties paid. Dr Liu reported receiving grant support from the University of Florida during the conduct of the study. Dr Mosa reported receiving grant support from PCORI, the Missouri Department of Health and Senior Services, and the National Institutes of Health (NIH) outside the submitted work. Dr Dixon reported receiving personal fees from Apellis Pharmaceuticals Inc, Novartis AG, Alexion AstraZeneca Rare Disease, Arrowhead Pharmaceuticals Inc, and Calliditas Therapeutics AB outside the submitted work. Dr Flynn reported receiving personal fees from UpToDate and an editorial stipend from International Pediatric Nephrology Association outside the submitted work. Dr Harshman reported receiving personal fees from Upsher-Smith Laboratories LLC outside the submitted work. Dr Modi reported receiving grant support from Phase V, Boehringer Ingelheim, and Travere Therapeutics Inc outside the submitted work. No other disclosures were reported. Dr Y. Chen reported receiving personal fees from Merck & Co Inc outside the submitted work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free